



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
---------------	-------------	----------------------	---------------------

08/028,795 03/08/93 FILLER

A UOFW16938

CASLER, B EXAMINER

33M1/1017

CHRISTENSEN, O'CONNOR,  
JOHNSON & KINDNESS  
2800 PACIFIC FIRST CENTRE  
1420 FIFTH AVE.  
SEATTLE, WA 98101

ART UNIT PAPER NUMBER

3305

DATE MAILED: 10/17/95

This is a communication from the examiner in charge of your application.  
COMMISSIONER OF PATENTS AND TRADEMARKS

☒ This application has been examined ☒ Responsive to communication filed on 7-10-95 ☒ This action is made final

A shortened statutory period for response to this action is set to expire 3 month(s), \_\_\_\_\_ days from the date of this letter.  
Failure to respond within the period for response will cause the application to become abandoned. 35 U.S.C. 133

Part I THE FOLLOWING ATTACHMENT(S) ARE PART OF THIS ACTION:

- |   |   |
|---|---|
| 1. <input type="checkbox"/> Notice of References Cited by Examiner, PTO-892.        | 2. <input type="checkbox"/> Notice of Draftsman's Patent Drawing Review, PTO-948. |
| 3. <input checked="" type="checkbox"/> Notice of Art Cited by Applicant, PTO-1449.  | 4. <input type="checkbox"/> Notice of Informal Patent Application, PTO-152.       |
| 5. <input type="checkbox"/> Information on How to Effect Drawing Changes, PTO-1474. | 6. <input type="checkbox"/>   |

Part II SUMMARY OF ACTION

1. ☒ Claims 89-100, 102-104, 106-115, 117-163 are pending in the application.  
Of the above, claims \_\_\_\_\_ are withdrawn from consideration.
2. ☒ Claims 101, 105, 106 have been cancelled.
3. ☒ Claims 102, 117, 130-138, 150-163 are allowed.
4. ☒ Claims 89-91, 97, 98, 108-110, 114, 115, 118, 119, 139-149 are rejected.
5. ☒ Claims 92-96, 99, 100, 103, 104, 106, 107, 111-113 are objected to.
6. ☐ Claims \_\_\_\_\_ are subject to restriction or election requirement.
7. ☐ This application has been filed with Informal drawings under 37 C.F.R. 1.85 which are acceptable for examination purposes.
8. ☐ Formal drawings are required in response to this Office action.
9. ☐ The corrected or substitute drawings have been received on \_\_\_\_\_. Under 37 C.F.R. 1.84 these drawings are ☐ acceptable; ☐ not acceptable (see explanation or Notice of Draftsman's Patent Drawing Review, PTO-948).
10. ☐ The proposed additional or substitute sheet(s) of drawings, filed on \_\_\_\_\_, has (have) been ☐ approved by the examiner; ☐ disapproved by the examiner (see explanation).
11. ☐ The proposed drawing correction, filed \_\_\_\_\_, has been ☐ approved; ☐ disapproved (see explanation).
12. ☐ Acknowledgement is made of the claim for priority under 35 U.S.C. 119. The certified copy has ☐ been received ☐ not been received ☐ been filed in parent application, serial no. \_\_\_\_\_; filed on \_\_\_\_\_.
13. ☐ Since this application appears to be in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.
14. ☐ Other

### Part III DETAILED ACTION

#### *Claim Rejections - 35 USC § 102*

The following is a quotation of the appropriate paragraphs of 35 U.S.C. § 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 89,91, 108 and 119 are rejected under 35 U.S.C. § 102(b) as being clearly anticipated by Hajnal et al.

Hajnal et al. teaches everything including MR imaging of structure within the nervous system that exhibits diffusion anisotropy in order to highlight desired structures and suppress other structures within the displayed image. Hajnal et al. accomplishes this by subjecting the subject to polarizing and excitation fields, detects a response and generates a corresponding output. The excitation fields include diffusion weighted gradients and the analysis includes outputting information representative of fascicles found in peripheral nerves.

#### *Claim Rejections - 35 USC § 103*

The following is a quotation of 35 U.S.C. § 103 which forms the basis for all obviousness rejections set forth in this Office action:

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as prior art only under subsection (f) or (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

Claims 90,97-98,109,110,114, and 118 are rejected under 35 U.S.C. § 103 as being unpatentable over Hajnal et al. in view of Suzuki et al. and further in view of Bydder et al.

Hajnal et al. teaches everything as stated supra and further teaches that it is essential to properly position and immobilize the patient. Hajnal et al. does not teach suppressing the fat around the nerves with a specific intensity of the enhanced tissue or using a splint to immobilize the patient.

Suzuki et al teaches everything including an apparatus and method for obtaining brain surface images which includes a polarizing field source, an excitation source, an output arrangement, a sequence controller, and a processor, and further teaches inhibiting the signals obtained from fat on the brain surface.

Bydder et al. teaches MR imaging of anisotropically restricted diffusion of water in tumors of the central nervous system in which patient immobilization was used to reduce artifacts due to patient motion.

It is the opinion of the examiner that motion artifacts and the various means to reduce the occurrence of patient movement during imaging are well known in the art and it is further well known to suppress or enhance various structures within an image to better localize and diagnose the tissue.

It would have been obvious at the time the invention was made to one of ordinary skill in the art to include in the device of Hajnal et al. a means for suppressing the fat surrounding the nerves being imaged as taught by Suzuki et al and to use any known means to reduce patient motion as is well known in the art and taught by Bydder et al.

Claim 115 and 140 is rejected under 35 U.S.C. § 103 as being unpatentable over Hajnal et al. in view of Suzuki et al and further in view of Gordon.

Hajnal et al. teaches everything as stated supra. Hajnal et al. does not teach using a contrast agent to enhance imaging or the use of phased array coils.

Gordon teaches the use of a phased array coil system, contrast agent and fat suppression techniques to enhance imaging.

It is the opinion of the examiner that the use of phased array coils in MR imaging is well known in the art. It would have been obvious at the time the invention was made to one of ordinary skill in the art to use a phased array coil system and a contrast agent in Hajnal et al. to enhance imaging as taught by Gordon.

Claims 139 and 144-149 are rejected under 35 U.S.C. § 103 as being unpatentable over Hajnal et al. in view of Suzuki et al.

Hajnal et al. teaches everything as stated supra. Hajnal et al. does not teach the specific imaging equipment to enhance nerve tissue.

Suzuki et al. teaches, as stated supra, an apparatus and method for obtaining brain surface images which includes a polarizing field source, an excitation source, an output arrangement, a sequence controller, a processor, and further teaches inhibiting the signals obtained from fat on the brain surface.

It is the opinion of the examiner that the equipment used to obtain an MR image is well known in the art. It would have been obvious at the time the invention was made to one of ordinary skill in the art to use the imaging system of Suzuki et al. in Hajnal et al. to obtain an image and suppress the desired tissues as taught by Suzuki et al.

Claims 141-143 are rejected under 35 U.S.C. § 103 as being unpatentable over Hajnal et al. in view of Suzuki et al. as stated supra and further in view of Sepponen.

Hajnal et al. teaches everything as stated supra including the need to immobilize the patient. Hajnal et al. does not teach the use of a splint to immobilize the patient or markers on the splint.

Sepponen teaches the use of markers on a frame to detect the frame position and reduce problems associated with patient movement.

It is the opinion of the examiner that various means to immobilize a patient are well known in the art. It would have been obvious at the time the invention was made to one of ordinary skill in the art to use a marked splint in Hajnal et al. to immobilize the patient to reduce motion artifacts and provide means for determining the position of the splint as taught by Sepponen.

*Allowable Subject Matter*

After further review of the prior art and applicant's amendments and remarks, the rejection of claims 92,95,103,104,106,107,112,and 113 are withdrawn.

Claims 92-96, 99-100,103,104,106,107, and 111-113 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Claims 102,117,120-138,150-161, and 162-163 are allowable over the prior art of record.

*Response to Amendment*

Applicant's arguments filed July 10, 1995 have been fully considered but they are not deemed to be persuasive.

Applicant argues that Hajnal et al. teaches only imaging tissue that is within the presence of dura matter, the arachnoid, and/or cerebrospinal fluid.

Although the specific examples are directed to nerves within the presence of dura matter, the arachnoid, and/or cerebrospinal fluid, on page 2, col. 2, lines 10-15, Hajnal et al. states that "The technique has also been applied to the spinal cord as well as to cranial and peripheral nerves." which is interpreted by the examiner to include nerves within cerebrospinal fluid as well as other peripheral nerves outside the spinal cord and any cranial nerves.

Further, it is the opinion of the examiner that the amendment to claim 89 is not sufficient to limit the nerve portion being imaged to that which is outside dura matter, the arachnoid, and/or cerebrospinal fluid.

Applicant further argues that the intended use of Suzuki et al. is different than applicant's intended use for fat suppression.

It is the opinion of the examiner that such an argument is moot in view of the actual claim language.

Applicant further argues that claim 110 encompasses suppression of blood vessels in the data set generated by applicant's method. Although, the actual claim language merely suggests that the region "may" include blood vessels.

In response to Applicant's argument that there is no suggestion to combine the references, specifically the Gordon reference, the Examiner recognizes that references cannot be arbitrarily combined and that there must be some reason why one skilled in the art would be motivated to make the proposed combination of primary and secondary references. In re Nomiya, 184 USPQ 607 (CCPA 1975). However, there is no requirement that a motivation to make the modification be expressly articulated. The test for combining references is what the combination of disclosures taken as a whole would suggest to one of ordinary skill in the art. In re McLaughlin, 170 USPQ 209 (CCPA 1971). references are evaluated by what they suggest to one versed in the art, rather than by their specific disclosures. In re Bozek, 163 USPQ 545 (CCPA) 1969. In this case, Gordon teaches the use of a contrast agent when imaging the spine.

In general, the use of contrast agents in such imaging procedures to enhance the imaging effects is well known, and it is the examiner's opinion that to use a contrast agent in another imaging procedure which includes imaging the spine, such as in Hajnal et al. would have been obvious to one of ordinary skill in the art at the time the invention was made as stated supra.

*Conclusion*

**THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 C.F.R. § 1.136(a).

A SHORTENED STATUTORY PERIOD FOR RESPONSE TO THIS FINAL ACTION IS SET TO EXPIRE THREE MONTHS FROM THE DATE OF THIS ACTION. IN THE EVENT A FIRST RESPONSE IS FILED WITHIN TWO MONTHS OF THE MAILING DATE OF THIS FINAL ACTION AND THE ADVISORY ACTION IS NOT MAILED UNTIL AFTER THE END OF THE THREE-MONTH SHORTENED STATUTORY PERIOD, THEN THE SHORTENED STATUTORY PERIOD WILL EXPIRE ON THE DATE THE ADVISORY ACTION IS MAILED, AND ANY EXTENSION FEE PURSUANT TO 37 C.F.R. § 1.136(a) WILL BE CALCULATED FROM THE MAILING DATE OF THE ADVISORY ACTION. IN NO EVENT WILL THE STATUTORY PERIOD FOR RESPONSE EXPIRE LATER THAN SIX MONTHS FROM THE DATE OF THIS FINAL ACTION.

The prior art submitted with the IDS in paper #15 on May 8, 1995, is unfortunately not with the present application.



The examiner requests applicant resubmit the following documents for consideration:


Foreign Documents


DE 3639140 A1	5/1987	Germany
WO 87/01199	2/1987	PCT
WO 91/17454	11/1991	PCT

Other Information

Howe, F. A. et al., "Magnetic Resonance Neurography", Magnetic Resonance in  
Medicine 28:328-338(1992)

Any inquiry concerning this communication or earlier communications from the  
examiner should be directed to Brian Casler whose telephone number is (703) 308-3552.

BLC/blc   
October 13, 1995

  
KRISTA M. ZELE  
PRIMARY EXAMINER  
GROUP 3300